Tatva Chintan Pharma Chem Limited (IN:TATVA)
:TATVA
Want to see IN:TATVA full AI Analyst Report?
TATVA Stock Chart & Stats
₹1388.35
-₹14.30(-1.60%)
At close: 4:00 PM EST
₹1388.35
-₹14.30(-1.60%)
Day’s Range― - ―
52-Week Range₹862.85 - ₹1,603.60
Previous CloseN/A
Volume13.99K
Average Volume (3M)12.52K
Market Cap
₹28.42B
Enterprise Value₹27.62B
Total Cash (Recent Filing)₹178.47M
Total Debt (Recent Filing)₹830.13M
Price to Earnings (P/E)68.0
Beta1.07
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.07%
Share Statistics
EPS (TTM)7.58
Shares Outstanding23,392,056
10 Day Avg. Volume25,333
30 Day Avg. Volume12,516
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.15
Price to Sales (P/S)4.87
P/FCF Ratio-29.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27
Revenue Forecast (FY)₹6.21B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow reported leverage (7.82B equity vs 1.20B debt) provides durable financial flexibility. This cushioning supports funding working-capital swings, customer qualification capex and temporary earnings volatility without immediate solvency pressure, enabling strategic investments.
Product And Market DiversificationA diversified specialty-chemicals mix (PTCs, electrolyte salts, pharma and agro intermediates) exposes the company to multiple structural end-market trends, including secular growth in energy storage and recurring demand from pharma/agro, reducing single-market cyclicality.
Revenue Recovery TrendA clear revenue rebound demonstrates renewed commercial traction and the ability to scale sales after contraction. Sustained top-line recovery can drive operating leverage, support margin restoration and validate earlier capacity or product qualification investments.
Bears Say
Weak Cash GenerationConsistent negative free cash flow indicates working-capital strain and/or heavy reinvestment needs. This raises funding risk, heightens reliance on the balance sheet or external financing, and constrains the company’s ability to self-fund growth, dividends or de-risk operations.
Volatile ProfitabilityEarnings swings and margins that trail prior peaks point to unstable cost/price dynamics or mix shifts. Persistent volatility undermines predictability of returns, complicates reinvestment decisions and weakens confidence that revenue recoveries will reliably translate to sustainable profits.
Recent Debt Increase RiskAlthough leverage is modest in absolute terms, the uptick in debt financing increases interest and refinancing risk if cash flows remain weak. If operating improvements stall, higher debt could restrict strategic flexibility and elevate balance-sheet vulnerability during downturns.
Tatva Chintan Pharma Chem Limited News
TATVA FAQ
What was Tatva Chintan Pharma Chem Limited’s price range in the past 12 months?
Tatva Chintan Pharma Chem Limited lowest stock price was ₹862.85 and its highest was ₹1603.60 in the past 12 months.
What is Tatva Chintan Pharma Chem Limited’s market cap?
Tatva Chintan Pharma Chem Limited’s market cap is ₹28.42B.
When is Tatva Chintan Pharma Chem Limited’s upcoming earnings report date?
Tatva Chintan Pharma Chem Limited’s upcoming earnings report date is Jul 29, 2026 which is in 54 days.
How were Tatva Chintan Pharma Chem Limited’s earnings last quarter?
Tatva Chintan Pharma Chem Limited released its earnings results on May 16, 2026. The company reported ₹4.7 earnings per share for the quarter, missing the consensus estimate of ₹6.4 by -₹1.7.
Is Tatva Chintan Pharma Chem Limited overvalued?
According to Wall Street analysts Tatva Chintan Pharma Chem Limited’s price is currently Overvalued.
Does Tatva Chintan Pharma Chem Limited pay dividends?
Tatva Chintan Pharma Chem Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.07%. See more information on Tatva Chintan Pharma Chem Limited dividends here
What is Tatva Chintan Pharma Chem Limited’s EPS estimate?
Tatva Chintan Pharma Chem Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tatva Chintan Pharma Chem Limited have?
Tatva Chintan Pharma Chem Limited has 23,392,056 shares outstanding.
What happened to Tatva Chintan Pharma Chem Limited’s price movement after its last earnings report?
Tatva Chintan Pharma Chem Limited reported an EPS of ₹4.7 in its last earnings report, missing expectations of ₹6.4. Following the earnings report the stock price went up 1.363%.
Which hedge fund is a major shareholder of Tatva Chintan Pharma Chem Limited?
Currently, no hedge funds are holding shares in IN:TATVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tatva Chintan Pharma Chem Limited
Tatva Chintan Pharma Chem Limited manufactures and sells specialty chemicals in India. The company offers a portfolio of structure directing agents for zeolites synthesis; phase transfer catalysts; electrolyte salts for super capacitor batteries; and pharmaceutical APIs, agrochemical products, and other specialty chemicals in the form of intermediates, disinfectants, catalysts, and solvents. It also provides quaternary compounds and quats, and bulk drugs, as well as trading of specialty chemicals. It serves various industries, including the automotive, petroleum, pharmaceutical, agro-chemicals, paints and coatings, dyes and pigments, personal care, and flavor and fragrances industries. The company also exports its products to approximately 25 countries. Tatva Chintan Pharma Chem Limited was incorporated in 1996 and is headquartered in Vadodara, India.
Technical Analysis
AARTI Industries Ltd
―
Alkyl Amines Chemicals Limited
―
Jubilant Ingrevia Ltd.
―
Rossari Biotech Ltd
―
Vinati Organics Limited
―